BIO:Dr Hermann has over 30 years of clinical drug development experience and has been a long-standing champion of model-informed drug development within the pharmaceutical industry. After receiving his Pharm.D. from the University of Illinois in 1988, Dr. Hermann completed a two-year fellowship in Clinical Research and Drug Development supported by the University of North Carolina and Glaxo. He then held various positions of increasing responsibility at Glaxo, Pharsight, and Pfizer. Responsibilities included representing Clinical Pharmacology on global project teams, leading early clinical development teams, crafting clinical development and dose selection strategies, and providing regulatory agency support. As a Pharsight consultant, Dr Hermann was responsible for devising and conducting Computer Trial Simulation projects and Modeling and Simulation training programs. In 2005, Dr Hermann received the BIO-IT World Grand Prize award for “Best Practices in Computational Biology and Informatics” for modeling and simulation work he led while at Pfizer. He then joined deCODE genetics where his responsibilities included managing the Clinical Pharmacology and Biostatistics groups. In 2008, Dr Hermann co-founded Great Lakes Drug Development (GLDD), a strategic drug development consultancy where he served as CEO & Head of Pharmacometrics. In August of 2013 GLDD was acquired by Pharsight/Certara. In 2017, Dr Hermann joined The Bill & Melinda Gates Foundation where he currently has the privilege of serving as Deputy Director of TB Drug Discovery and Development. In this role he is responsible for guiding investment strategies to shepherd the next generation of TB therapeutics.